NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung ...

Astrazeneca is set to report earnings next week after a turbulant few months for the FTSE 100 firm and its China arm.

AstraZeneca’s hopes of positioning its PD-L1 inhibitor Imfinzi as a post-surgery therapy for people with earlier-stage lung cancer have taken a knock, although it performed well in a bladder ...

The new indication adds to Imfinzi's FDA-approved indications in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), which have helped drive sales of the PD-L1 inhibitor to $1.3 ...

Key Takeaways Zacks earnings estimates for AstraZeneca are currently at $4.06 per share. However, the earnings picture ...

Chavez, MD, discusses the efficacy of immunotherapy for the potential treatment of extensive-stage small cell lung cancers.

Its product lineup is anchored by its oncology offerings, with drugs including Enhertu, Tagrisso, and Imfinzi as key ...

One option is an immunotherapy medicine called Imfinzi (durvalumab). Immunotherapy medicines work by helping your immune system find and attack cancer cells. The FDA approved Imfinzi in 2017.

Now, a newer option is available: an immunotherapy medicine called Imfinzi (durvalumab). Immunotherapy medicines work by helping your immune system find and attack cancer cells. The FDA approved ...

The pharma giant confirmed that Wang Lei, the executive vice president who oversaw AstraZeneca’s rapid expansion in China, is ...

Other key accomplishments and milestones in 2024 include: Metastatic Pancreatic Ductal Adenocarcinoma Commenced enrollment ...

These include cancer drugs Tagrisso, Imfinzi, Lynparza, and Calquence, all of which carry "strong pricing power to support higher margin sales." This pricing power should set AstraZeneca up for ...